BioSpace News Archive

Taro Pharmaceutical Industries Ltd. provided unaudited financial results for the quarter and six months ended September 30, 2022.

DexCom, Inc. reported its financial results as of and for the quarter ended September 30, 2022.

According to Nova one advisor, the global Cancer Diagnostics market size was valued at USD 160.9 billion in 2021 and is predicted to hit USD 293.8 billion by 2030 with a registered CAGR of 6.90% during the forecast period 2022 to 2030.

BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) (“BioMark”) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today the publication of a preclinical study demonstrating therapeutic capabilities of its SAT1 cancer marker in glioblastoma (GB) cells using an ionizable lipid nanoparticle

Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (“Therma” or the “Company”), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies

Researchers using the DELFI platform, a technology for a new class of high performance, accessible liquid biopsy tests being commercialized by Delfi Diagnostics, Inc., will present new data demonstrating its ability to accurately detect liver cancer in high risk and average risk individuals at The Liver Meeting 2022.

Rutgers University is teaming up with Quest Diagnostics to provide no-cost laboratory tests over the next year to diagnose and manage acute and chronic diseases for uninsured and underinsured patients of the university’s H.O.P.E. Clinic in Plainfield, N.J.

Vyluma, Inc., a biopharmaceutical company developing multiple assets for the treatment of refractive errors, announced top-line results from its Phase III CHAMP clinical study.

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced that data from multiple studies of LUPKYNIS® (voclosporin) will be presented at the American Society of Nephrology (ASN) Kidney Week 2022, taking place November 3-6 in Orlando, Florida.

Bayer’s KERENDIA® (finerenone) was recommended as part of a comprehensive treatment strategy for patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D) in a newly published update to the Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease and in a consensus report jointly issued by KDIGO and the American Diabetes Association (ADA).